The Cross-Border Biotech Blog

MondayDealTitle

Welcome to your Monday Biotech Deal Review for September 15th, 2014!   The last few weeks saw a steady rise in activity, with a series of financings being announced as well as closed. The Allergan-Valeant-Pershing Square saga also continues, as Allergan has requested an expedited schedule to obtain a preliminary injunction against Valeant in hopes […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for August 22nd, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. This week’s Canada in Science Review includes our first highlighted paper from Saskatoon, home of […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for August 18th, 2014!   The past week saw Valeant continue its aggressive bid for shares of Allergan, with Valeant extending the expiration of its exchange offer to December 31, 2014.  On the financing side, Supreme Pharmaceuticals has announced a private placement worth up to $5 million in […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for August 15th, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. This week’s selection of research articles from across Canada delves into almost all the […]

read more


Monday Deal Review – August 11, 2014

Welcome to your Monday Biotech Deal Review for August 11th, 2014!   As Monday, August 4th was a holiday here in the great white north, today’s post covers the last two weeks’ worth of activity. On the M&A front, Nordion has closed their plan of arrangement with Sterigenics, giving former Nordion shareholders $13.00 for each […]

read more


Canada in Science – August 8, 2014

Welcome to your Canada in Science Review for August 8th, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. This week’s selection of exciting research from across Canada spans reports on large diabetes […]

read more


Canada in Science – August 1, 2014

Welcome to your Canada in Science Review for August 1st, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. The foundations of the next generation of Canadian healthcare companies could well be found […]

read more


Monday Deal Review – July 28, 2014

Welcome to your Monday Biotech Deal Review for July 28th, 2014!   The past weeks saw significant activity in the financing space, with Tribute closing their public offering, worth approximately $30 million in the aggregate. Spectral and Zenith on the other hand have closed private offerings of their own, obtaining proceeds of $13.2 million and […]

read more


Q2 2014 Share Price Performance (Part 2)

    Momentum more selective in Q2 but still overall positive share price performance in H1 2014 for the Canadian Healthcare Sector (Part 2) In this blog, I am going to comment on the Q2 performance of the group of 60 companies with share prices of between $0.10 and $0.99 to start 2014. Q2 Results […]

read more


Monday Deal Review – July 14, 2014

Welcome to your Monday Biotech Deal Review for July 14th, 2014!   After a shortened week in both the US and Canada, things have picked up nicely in both the M&A and financing spaces, with Resverlogix, Spectral Diagnostics, Immunotec, Merus Labs, Helix BioPharma, Valeant and Knight each making news.   For details on these companies as […]

read more